Adriana Rossi

Research interests

Publications

• Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

  Journal of Clinical Oncology · 2025 · 10.1200/jco-25-00760

• Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

  Journal of Hematology & Oncology · 2024 · 10.1186/s13045-024-01555-4

• Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

  Blood Advances · 2024 · 10.1182/bloodadvances.2023012470

• Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience

  Transplantation and Cellular Therapy · 2023 · 10.1016/j.jtct.2023.01.012

• IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

  Blood Cancer Discovery · 2023 · 10.1158/2643-3230.bcd-23-0049

• BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

  Blood · 2023 · 10.1182/blood-2023-181857

• Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma

  Blood Advances · 2022 · 10.1182/bloodadvances.2022007923

• Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

  Blood · 2022 · 10.1182/blood.2022017848

• Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies

  Blood · 2022 · 10.1182/blood-2022-163733

• Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

  Blood · 2022 · 10.1182/blood-2022-165646

• Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

  British Journal of Cancer · 2021 · 10.1038/s41416-021-01608-2

• Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

  BMC Cancer · 2021 · 10.1186/s12885-021-08881-7

• COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers

  medRxiv · 2020 · 10.1101/2020.06.09.20126516

• Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

  eJHaem · 2020 · 10.1002/jha2.122

• COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

  Blood Cancer Discovery · 2020 · 10.1158/2643-3230.bcd-20-0102

• Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk

  Leukemia & lymphoma/Leukemia and lymphoma · 2019 · 10.1080/10428194.2018.1543877

• BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma

  Blood · 2013 · 10.1182/blood-2012-08-448563

• Determination of thyroid volume by Sonography in healthy Brazilian schoolchildren

  Journal of Clinical Ultrasound · 2002 · 10.1002/jcu.10060

• Mortality from cancer and chronic respiratory diseases among workers who manufacture carbon electrodes

  Occupational and Environmental Medicine · 2000 · 10.1136/oem.57.7.484

• Predicting outcome after listing for heart transplantation in children: comparison of Kaplan-Meier and parametric competing risk analysis. Pediatric Heart Transplant Study Group.

  PubMed · 1997

Current projects

No projects listed.